Skip to Main Content

2018 Events

  • Scripps Florida HTS & Strategies for the Discovery & Advancement of Small Molecule Drug-like Leads - Sept. 21

    Friday, Sept. 21, 2018, 12pm-1pm, AHC4 402

    Dr. Louis Scampavia and Dr. Timothy Spicer, co-Directors, Scripps Research Molecular Screening Center, will give a talk. The Molecular Screening Facility at Scripps Research Florida has a state-of-the-art HTS operation to support both intramural and extramural HTS needs.

    HTS co-Directors: Louis Scampavia & Timothy Spicer

    HTS co-Directors: Louis Scampavia & Timothy Spicer

     

    The Molecular Screening Facility at Scripps Research Florida has a state-of-the-art HTS operation to support both intramural and extramural HTS needs. This facility has both HTS and compound management robotic automation and the expertise in adapting biological and biochemical bench-top assays for HTS. The Scripps Drug Discovery Library curates over 665,000 small drug-like compounds, containing a number of targeted sub-libraries.

    High-Throughput Screening (HTS) is a drug-discovery process widely used in both academia and the pharmaceutical industry. It leverages automation to quickly assay the biological or biochemical activity of a large number of drug-like compounds for the discovery of novel small molecule ligands against: receptors, enzymes, ion-channels and other pharmacological targets, or pharmacologically profiling a cellular/biochemical pathway of interest. The Molecular Screening Facility at Scripps Research Florida has a state-of-the-art HTS operation to support both intramural and extramural HTS needs. This facility has both HTS and compound management robotic automation and the expertise in adapting biological and biochemical bench-top assays for HTS. The Scripps Drug Discovery Library curates over 665,000 small drug-like compounds, containing a number of targeted sub-libraries. Presented is an introduction to the Scripps Florida HTS facility and its capabilities as well as strategies used in the discovery of small molecule drug-like leads.

  • Mycobacteria: TB and not TB - Sept. 12

    Wednesday, Sept. 12, 2018, 3pm-4pm, CP 117

    Dr. Rashmi Gupta, Research Associate, Burnett School of Biomedical Sciences, University of Central Florida, will be giving a talk. Dr. Gupta is visiting FIU as an AFN-WISE awardee to conduct research seminar, develop collaborations, and build networks. She is developing her research in pathogenesis, drug resistance, drug screening and drug discovery for respiratory pathogens including Pseudomonas aeruginosa, Mycobacterium tuberculosis and Mycobacterium abscessus.

  • Lunch and Q&A's with International Expert on Skin, Aging & Mitochondria - May 29

    Tuesday, May 29, 2018, 12pm-1pm, AHC4 402

    Dr. Mark Birch-Machin from Newcastle University Institute of Cellular Medicine will host a lecture. His research group focuses on the response of human skin to ultraviolet radiation particularly within the context of skin aging and cancer, particularly involving the role of mitochondria.

    Mark Birch-Machin, Ph.D., is Professor of Molecular Dermatology and Associate Dean (Business Development and Commercial Interface) at the Newcastle University Institute of Cellular Medicine. Prof. Birch-Machin pursued his Post-Doctoral career at the University of Oregon (USA), INSERM Paris, and the University of Toronto, as well as Clinical Neuroscience and Biochemistry, Newcastle University (1986-1995) where he held several academic positions in the Department of Dermatology (1996-current). During this time, he was elected Treasurer of the British Society of Investigative Dermatology (BSID) and co-editor of Experimental Dermatology. He advanced to the position of Professor of Molecular Dermatology at Newcastle University in 2005 and Associate Dean in 2014.

    His research group focuses on the response of human skin to ultraviolet radiation, particularly within the context of skin aging and cancer which involve the role of mitochondria. He has published extensively including in three different Nature journals. He also has interest in understanding the role of mitochondrial DNA in UV-induced oxidative stress, cancer and the relationship between oxidative stress, nutritional status and skin aging as well as the science and use of sunscreens.

    Dr. Birch-Machin has received research funding (multi-million total) from Cancer Research UK, British Skin Foundation, BBSRC, MRC, EPSRC, Wellcome Trust, NESRF, KTP, BRC, Innovate UK, NC3R, Royal Society and global commercial companies. In addition, he is also a co-inventor on multiple patents arising from the commercialization of parts of this research, including the invention of a product that sold in over a 1000 stores in Canada as part of a Canadian spin-out company which Mark co-founded in 2003. In 2010, he was awarded the Newcastle University Spirit of Entrepreneurship Award and has gone on to be a co-founder of a second spin-out company in 2012 which is now called PB Bioscience. Prof. Birch-Machin has been an internationally and nationally invited keynote speaker at numerous prestigious conferences and symposia. He has been Chair of several international Scientific Advisory Boards; member of the Cancer Research UK sunsmart advisory board, expert advisor for Clearcast, RACC and the ASA, and is a member of the grants awarding committee for the British Skin Foundation as well as the Editorial board for Experimental Dermatology.

    A regular National Press Spokesperson, Prof. Birch-Machin has given talks on ‘Sunburnt DNA,’ DNA damage, skin aging and skin cancer risk related to his current and previous roles with national skin charities. His research and quotes on sun awareness have appeared on multiple European and American TV segments (including 9 full TV programmes on BBC, ITN, Sky, Discovery), more than 200 radio programs, online columns, over 250 national and local UK newspapers and over 200 popular magazine articles. In addition, he has regularly and extensively contributed to the national education of sun-awareness using the popular media as well as public lectures (The Royal Institution and The Wellcome Collection). He has also given a mini-roadshow on sun-awareness to local schools and is a regular Invited Public Speaker at the Discovery Museum Science Show (Newcastle) as well as an ‘expert’ speaker at the European Union Excellence in Cities - Specialist Bioscience Summer School (EU funded).

    As the original Degree Programme Director, Prof Birch-Machin designed, created and managed the team which administers the MRes in Medical and Molecular Biosciences that in two years became the largest postgraduate taught programme in the Faculty of Medical Sciences. Prof Birch-Machin has various University/Faculty positions including Chairing the Faculty Business Opportunities committee and the Faculty Commercialisation committee.

  • IMS-MS as a means of revealing new states during the melting of proteins - April 13

    Friday, April 13, 2018, 12pm-1pm, AHC4 402

    Dr. David Clemmer, Distinguished Professor from Indiana University Bloomington, will host a lecture.

  • Dr. Laura Finzi of Emory College will host a lecture - March 30

    Friday, March 30, 2018, 1:30pm-2:30pm, GL 100A

    Dr. Laura Finzi from Emory College will host a lecture. Her research interests are single-molecule biophysics of transcriptional regulation.

  • Type IA Topoisomerases can be "magicians" for both DNA and RNA - Feb. 2

    Friday, Feb. 2, 2018, 11am-12pm, DM 100

    Dr. Weidong Wang, Senior Investigator, Laboratory of Genetics at the National Institutes of Health, will host a lecture on Type 1A Topoisomerases for both DNA and RNA.